Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

India’s ‘Cautious’ View Dulls Sanofi Hopes For Early Dengvaxia Launch

Executive Summary

An early rollout of Sanofi Pasteur’s dengue vaccine in India is looking less likely with a senior functionary of the health ministry telling Scrip why India needs to take a “cautious view” on the product’s licensure in the country, at least for now. Sanofi, though, has sought the “best regulatory solution” that can facilitate access to the product.

You may also be interested in...



Brakes On Sanofi’s Dengvaxia Prospects Amid WHO-SAGE Screening Advice?

WHO’s recommendation around a pre-vaccination screening strategy for Sanofi’s Dengvaxia could potentially dull the prospects of the product further, especially in emerging markets with stretched healthcare resources. One industry expert suggests that governments should probably consider introducing the vaccine only after “better tests and tools” become available.

First Zika Cases Reported In India; Government Says No Need For Panic

WHO reports confirmation of three cases of Zika infection in the western state of Gujarat but a top Indian government official assures there’s no need for “panic” as there have been no fresh reports of the virus in months. Hyderabad-based Bharat’s Zika vaccine cleared to begin Phase I trials.

Come Flood Or High Water – How BioNet Is Shaping Its Vaccine Ambitions

Emerging Company Profile: Thailand-based BioNet stuck it out despite widespread flooding at its site and now expects to take its pertussis vaccine to key Western markets.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC098203

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel